Cited by 120Gut microbiota and healthGastrointestinal motility and disordersDiabetes Treatment and Management

The DOI matches its Crossref record; 271 of the 272 references it cites were found in a registry or an index.

Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease

Open access

Masse, Karly E., Lu, Van B.·2023·Frontiers in Endocrinology

DOI 10.3389/fendo.2023.1169624PMC PMC10407565

Open this paper in CoChat — free account Open PDF

Abstract

The gastrointestinal tract hosts the largest ecosystem of microorganisms in the body. The metabolism of ingested nutrients by gut bacteria produces novel chemical mediators that can influence chemosensory cells lining the gastrointestinal tract. Specifically, hormone-releasing enteroendocrine cells which express a host of receptors activated by these bacterial metabolites. This review will focus on the activation mechanisms of glucagon-like peptide-1 releasing enteroendocrine cells by the three main bacterial metabolites produced in the gut: short-chain fatty acids, secondary bile acids and indoles. Given the importance of enteroendocrine cells in regulating glucose homeostasis and food intake, we will also discuss therapies based on these bacterial metabolites used in the treatment of metabolic diseases such as diabetes and obesity. Elucidating the mechanisms gut bacteria can influence cellular function in the host will advance our understanding of this fundamental symbiotic relationship and unlock the potential of harnessing these pathways to improve human health.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3389/fendo.2023.1169624

Cites

271 of 271 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Schematic representation of the bidirectional relationship between the host-gut microbiota equilibrium and metabolic health. Cells lining the distal gastrointestinal tract are in direct contact with bacterial metabolites produced by the gut microbiota, and thus can contribute to host health. In a healthy state, the gut microbiota produces metabolites that activate receptors on distal EECs to mediate insulinotropic effects by the release of secretory vesicles containing GLP-1. Gut dysbiosis alters the intestinal composition and metabolites produced and is associated with the development of T2DM and obese-related diseases. Research has proposed that the dysregulation of metabolism in metabolic diseases releases molecules that can reduce the abundance of intestinal bacteria and alter the function of the ecosystem. EEC, enteroendocrine cell; GLP-1, glucagon-like peptide-1; T2DM, type 2 diabetes mellitus.CC BY · PubMed Central

Figure 2 SCFA-triggered intracellular signaling mechanisms in GLP-1 releasing EEC L-cells. Schematic of an L-cell (white) surrounded by enterocytes (grey). Complex carbohydrates are substrates for resident gut bacteria to produce SCFAs in the distal gastrointestinal tract. SCFAs can signal through multiple receptors on both the apical (top) and basolateral membranes (bottom) of L-cells. Uptake of SCFAs by SMCT and MCT across the intestinal epithelium to the basolateral side shown in enterocytes. SCFAs inhibit HDACs or activate G-protein coupled receptors FFA2, FFA3 and OR51E1/2 in L-cells. Unresolved mechanisms are marked with a question mark. EEC, enteroendocrine cell; SCFAs, short-chain fatty acids; FFA2/3, free fatty acid receptor 2 or 3; OR51E1/2, olfactory receptor subfamily 5E1 or 2; GLP-1, glucagon-like peptide-1; Ca2+, calcium ions; SMCT, sodium-dependent monocarboxylate transporter; MCT, H+-dependent monocarboxylate transporter; Na+, sodium ions; HDACs, histone deacetylases; AC, adenylyl cyclase; cAMP, cyclic adenosine monophosphate; PLCβ, phospholipase C beta; ERK1/2, extracellular signal-regulated kinases; IP3, inositol triphosphate.CC BY · PubMed Central

Figure 3 Secondary bile acid-triggered intracellular signaling mechanisms in GLP-1 releasing EEC L-cells. Schematic as in Figure 2. Primary bile acids are converted to secondary bile acids by intestinal gut bacteria. Secondary bile acids passively diffuse or are transported across the intestinal epithelium via ASBT and activate the G-protein coupled receptor, GPBAR1 and nuclear receptor, FXR. Activation of GPBAR1 by secondary bile acids results in GLP-1 secretion. FXR regulates SHP and FGF19 expression and may regulate GPBAR1 gene transcription (marked by a question mark). EEC, enteroendocrine cell; GPBAR1, G-protein coupled bile acid receptor; FXR, Farnesoid-X receptor; GLP-1, glucagon-like peptide-1; ASBT, apical sodium-dependent bile acid transporter; Ca2+, calcium ions; AC, adenylyl cyclase; cAMP, cyclic adenosine monophosphate; ATP, adenosine triphosphate; SHP, short heterodimer protein; FGF19, fibroblast growth factor 19; Na+, sodium ions.CC BY · PubMed Central

Figure 4 Indole-triggered intracellular signaling mechanisms in GLP-1 releasing EEC L-cells. Schematic as in Figure 2. Tryptophan is a substrate for resident gut bacteria to produce the metabolites tryptamine, IPyA and indoles. IPyA is a precursor to the metabolites IAA, IAld, skatole and IPA. Indole and other metabolites passively diffuse across the intestinal epithelium and activate the transcription factors AhR and PXR to regulate gene transcription. Indole may mediate effects through a yet to be determined receptor. There are dual and opposing effects on GLP-1 release by acute and chronic exposure to indoles. Acute indole stimulates release of secretory vesicles containing GLP-1 by a voltage-gated potassium channel blockade. Chronic indole exposure suppresses mitochondrial activity to produce ATP. IPyA, indole-3-pyruvic acid; IAA, indole-3-acetic acid; IAld, indole-3-aldehyde; IPA, indole-3-propionic acid; EEC, enteroendocrine cell; AhR, Aryl hydrocarbon receptor; PXR, Pregnane-X-receptor; ψ, membrane potential; K+, potassium ions; Ca2+, calcium ions; ATP, adenosine triphosphate.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,820
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762 · cited 1×
“In earlier studies, obesity and insulin resistance were associated with an increased abundance of Bacillota and concomitant decrease of Bacteroidota in both animal (7, 168), and human studies (6, 167, 169).”
Background
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245 · cited 1×
“Dysbiosis of host-gut microbiota equilibrium may precede metabolic disease as similar shifts in intestinal gut bacteria composition can disrupt nutrient and energy metabolism (9).”
Background
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176 · cited 1×
“In earlier studies, obesity and insulin resistance were associated with an increased abundance of Bacillota and concomitant decrease of Bacteroidota in both animal (7, 168), and human studies (6, 167, 169).”
Background
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425 · cited 1×
“Interestingly, the distal small intestine and colon harbor the greatest density of PYY and GLP-1 releasing L-cells (41), paralleling the distribution of gut bacteria (42).”
Background
Host-Bacterial Mutualism in the Human Intestine
Bäckhed, F., Ley, R. E., Sonnenburg, J. L., Peterson, D. A., & Gordon, J. I. (2005) · Science · doi:10.1126/science.1104816 · Cited by 5,277 · cited 1×
“In earlier studies, obesity and insulin resistance were associated with an increased abundance of Bacillota and concomitant decrease of Bacteroidota in both animal (7, 168), and human studies (6, 167, 169).”
Background
The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism
den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., & Bakker, B. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036012 · Cited by 5,048 · cited 2×
“The absorbed butyrate is largely utilized by colonocytes for energy, and the remaining absorbed SCFAs are transported through portal blood circulation back to the liver where SCFAs are primarily converted to glucose stores (4).”
Background
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639

Show all 272 references

Sorted by citations

Items 101–120 of 120

Restoring Microbial Signaling: A Metabolite–Immune–Redox Framework for Postbiotic Host-Directed Interventions
Bajić, D., Todorović, N., Lalic-Popovic, M. N., Vučković, J., Mihajlović, A., Slavić, D., Tapavički, B., Stojsic, M., & Milosevic, N. P. (2026) · Medical Sciences · doi:10.3390/medsci14040438
“Emerging evidence suggests that butyrate may influence Nrf2-linked cytoprotective responses, support mitochondrial efficiency, and redirect inflammatory metabolism away from oxidative injury toward adaptive resilience [6,20,31].”
Effects of Hedan Tablets Combined With Simvastatin on Hyperlipidemia: Insights From Microbiomics and Metabolomics
Gao, R., Zhang, Y., Zhang, Z., Zhao, C., & Zhao, M. (2026) · Biomedical Chromatography · doi:10.1002/bmc.70559
From microbial dysbiosis to putative epigenetic locking: a hypothesis-driven framework for the pathogenesis and future therapeutic perspectives of gastric intestinal metaplasia
Sheng, Y., Chaosheng, Y., Yin, Y., Zeng, Z., Pei, X., Ma, C., Rao, J., haowen, S., & Xue, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08730-w
“…in health may include microbiota-associated short-chain fatty acids, such as butyrate and propionate, whereas pathological states may involve microbial metabolic changes together with host-or reflux-related metabolic inputs; however, gastric IM-specific metabolomic evidence remains limited [90].”
Magnesium and Rapamycin in Long Covid and Longevity: Mechanistic (Part A) and Therapeutic (Part B) ProposalsPreprint
Chambers, P. W. (2026) · Qeios · doi:10.32388/u5jtwn.3
Gut microbiota-derived TMA/TMAO and IRAK4 signaling in type 2 diabetes: Current evidence, knowledge gaps and future therapeutic opportunities
Sarma, A. D., Devi, M., Kumar, D., & Choudhary, N. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117240
The liver–gut–brain axis in metabolic dysfunction-associated steatotic liver disease: bidirectional communication, clinical implications, and future perspectives
Ren, Y., Hu, D., Li, L., Wang, L., & Meng, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1911290
“SCFAs, particularly butyrate, support colonocyte energy metabolism, epithelial integrity, and context-dependent immune regulation (26, 27).”
Natural products for depression: Preclinical insights into microbiota–gut–brain axis modulation and pharmacological potential
Qiao, X., Han, D., Bai, Y., Wang, R., Xue, X., Wang, Z. X., Jin, M. H., & Tao, R. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108390
The gut microbiome organ
Bi, Y., Song, W., Glymenaki, M., Hu, J., Li, X., Huang, H., Peng, Y., Ni, S., Haonon, O., Liu, Z., et al. (2026) · iMeta · doi:10.1002/imt2.70144 · Cited by 1
3-substituted indole derivatives as potential drug candidates: Lipophilicity, solubility, drug-likeness, and VEGFR2 binding studies
Shukla, N., Das, R., Arthur, D. E., Serdaroğlu, G., Dangi, H., Altunoluk, O. C., & Özbek, O. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110426
The Gut Microbiome as a Mechanistic Link Between the Planetary Health Diet and Healthy Aging
Jarecsny, T., Ceglédi, A., Csípő, T., Fazekas‐Pongor, V., Mózes, N., Csík, B., Zábó, V., Lipécz, Á., Nyáry, D., & Fekete, M. (2026) · Nutrients · doi:10.3390/nu18172864
“SCFAs promote glucagon-like peptide-1 (GLP-1) secretion, thereby linking microbial metabolism with improved glycemic regulation, insulin sensitivity, and appetite control [88–96].”
Microbiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the Lifespan
Kalafati, I. P., Krongauz, D. L., Bosco, A., Noto, A., Piras, C., Kafyra, M., Dessì, A., Mauri, M., Atzori, L., Weinberger, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70220
Effects of Dietary Glucose, Fructose, and Monosaccharide-to-Lard Energy Ratios on Cecal Microbiota Composition and Ecological Organization in Rats
Szabó, J., Maróti, G., Solymosi, N., Andrásofszky, E., Tuboly, T., Bersényi, A., Bruckner, G. G., & Fébel, H. (2026) · Nutrients · doi:10.3390/nu18172875
“Members of this phylum play important roles in the fermentation of complex dietary substrates and include major producers of short-chain fatty acids (SCFAs), particularly butyrate, which contributes to intestinal barrier integrity, immune homeostasis, and host energy metabolism [27,28].”
Insights into Microbiota–Vaccine Crosstalk in Humans: Mechanisms, Modulators, and Translational Horizons
Shakri, A. R., Mishra, S. P., Lawless, S., Pani, S., Mishra, P., Page, C. L., Dutta, G., & Sharma, C. (2026) · Vaccines · doi:10.3390/vaccines14090791
“Some postbiotics can also act as safe, microbe-derived adjuvants [22,23].”
Gut microbiota as a modulator of HDAC: insights into Alzheimer’s disease treatment
Verma, E., Mishra, S., Chellammal, H. S. J., Khandige, P. S., & Gasmi, A. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00897-9 · Cited by 1
MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo
Laperrousaz, B., Reygner, J., Seilhac, M. D., Sabourin, A., Bompard, C., Gasc, C., Prestat, E., Levast, B., Petitjean, C., Declomesnil, S., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1920614
From Food Structure to L-Cell Exposure: How Processing and Digestion Shape Endogenous GLP-1 Responses
Šantić, R., Kumrić, M., Kurir, T. T., Rušić, D., & Božić, J. (2026) · Molecules · doi:10.3390/molecules31193375
“Reviews that group short-chain fatty acids, bile acids, and indoles as signalling between the microbiome and GLP-1 risk obscuring their opposing actions and dependence on molecular structure [88].”
Neuroendocrine regulation of appetite and energy balance in metabolic disorders
Khatun, M. M., Sarker, M. N. A., Biswas, M. S., Podder, M. K., & Akter, S. (2026) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2026.09.017
Bifidobacterium adolescentis SBT2786-induced early-night sleep requires CCHamide-1 signaling in Drosophila ellipsoid body ring neuron circuits
Murakami, H., & Kobayashi, S. (2026) · iScience · doi:10.1016/j.isci.2026.117683
Gut microbiota - γδT cells axis: mechanisms of immunoregulation and therapeutic opportunities.
Wang, M.-L., He, Y.-L., Zhuo, F.-R., & Xu, J.-L. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117509
Is There a Relationship Between the Gut Microbiome and the Functional Capabilities of Skeletal Muscle? A Narrative Review
Ondrak, K. S., Seicshnaydre, E. A., Duffy, S., Rodriguez, C. L., Scott, C., Gladish, S., & Byerley, L. O. (2026) · Nutrients · doi:10.3390/nu18193300
“Regulate muscle metabolism through FXR and TGR5 signaling pathways, influence energy expenditure, mitochondrial activity, and maintenance of muscle mass and function [27,28].”

Authors: Masse, K. E., & Lu, V. B.
Affiliations: Western University (CA)
Corresponding author: Lu, Van B.
ORCID: Lu, Van B.
Venue: Frontiers in Endocrinology
Publisher: Frontiers Media SA
Published: 2023-07-25
Volume: 14
Pages: 1169624-1169624
ISSN: 1664-2392 (ISSN-L)
DOI: 10.3389/fendo.2023.1169624
PMC: PMC10407565
OpenAlex: W4385251361
Cited by: 120
References: 272
Citations by year: 2026: 66 · 2025: 23 · 2024: 29 · 2023: 2
FWCI: 3.16
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Frontiers in Endocrinology (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: Natural Sciences and Engineering Research Council of Canada
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords: short-chain fatty acids, secondary bile acids, indole, gut microbiota metabolites, enteroendocrine cells, glucagon-like peptide-1, glucose homeostasis, food intake regulation, diabetes mellitus, obesity, metabolic disease treatment, gut microbiota, host-microbe symbiosis
MeSH terms: Gastrointestinal Microbiome, Bacteria, Bile Acids and Salts, Fatty Acids, Volatile, Humans, Indoles, Metabolic Diseases, Ecosystem, Enteroendocrine Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks